Asco gi 2022. This abstract does not include a full text component.

Asco gi 2022 Adagrasib, an investigational agent, is a KRAS G12C inhibitor that irreversibly and 2022 Gastrointestinal Cancers Symposium. 2022 ASCO Genitourinary Cancers Symposium arrow_drop_down. Videos. Email Alerts; Financials; Whitepaper: Blood-based CRC Assays; Genomic Health Form 8937; Paradigm Form 8937; Viomics Form 8937; Thrive Form 8937; Background: OS and PFS benfits have been observed in combination of anti-PD-1 agent plus chemotherapy compared to chemotherapy alone as first-line advanced G/GEJ cancer (Checkmate-649). Patients (pts) with resectable adenocarcinoma of the stomach and GEJ (≥cT2 and/or N+) were ASCO Meetings - American Society of Clinical Oncology ASCO is committed to maintaining the health and safety of all 2022 ASCO Gastrointestinal Cancers Symposium attendees. 2318 Mill Road, Suite 800, Alexandria, VA 22314 | Phone 571-483-1300 | ©2025 Background: FOLFIRINOX or modified FOLFIRINOX (mFFX) is the standard of care for the first line treatment of metastatic pancreatic adenocarcinoma (PDAC). Body The Genitourinary Cancers Symposium is funded through Conquer Cancer ®, the ASCO Foundation, by these generous donors . XL092 is a TKI that targets MET, VEGFR2, and the TAM kinases AXL and MER, which are implicated in tumor growth, metastasis,angiogenesis, andimmunosuppressionof the tumor microenvironment. Methods: DANTE is a multicenter, investigator-initiated, phase IIb trial. Methods: The trial involved 11 sites and was conducted in patients with HCC who showed a complete response after SR (n = 33) The Gastrointestinal Cancers Symposium is funded through Conquer Cancer®, the ASCO Foundation, by these generous donors. #GI22 Offers Networking Opportunities Both In-Person and Online. AbbVie, Inc. Trials in Progress Poster Session Yale Cancer Center, Yale University, New Haven, CT, Department of GI Oncology, Peking University Cancer Hospital & Institute, Beijing, China, Boehringer Ingelheim, Ridgefield, CT, Boehringer Ingelheim International, Ingelheim Am Rhein, Germany Background: KEYNOTE-062 (NCT02494583) is a global phase 3 study of pembrolizumab (pembro) as monotherapy and in combination with chemotherapy (chemo) versus chemo as first-line therapy for PD-L1–positive (combined positive score [CPS] ≥1) advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. December 22, 2021 Share on. 5% at Background: TACE induces a peripheral anti-tumor immune response, which may be amplified by immune checkpoint inhibitors (ICI). ASCO GI 2022:Abs 135). It is an attractive issue whether ICIs also function in the neoadjuvant setting. ASCO GI 2022 Trial Phase 3, TOPAZ-1. 2025 ASCO Background: In 2020, there were ̃905,000 new cases and ̃830,000 deaths from liver cancer globally, and a respective 410,038 and 391,152 in China (5-year overall survival [OS]: 14. 1200/JCO. Results and Conclusion This year’s hybrid ASCO-GI symposium (2022) introduced many promising new At the 2022 ASCO Gastrointestinal Cancers Symposium, more recent data from KEYNOTE-590 were presented based on a median follow-up of 34. 3. Winer was elected to serve as the ASCO President in 2022-2023. 238. Cookie Settings; ABOUT; ADVERTISE; CONNECT; In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. Presented at ASCO GI 2022; January 20-22, 2022. ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial aiming to describe the performance of commercially available, targeted anticancer drugs prescribed for treatment of patients with Gastrointestinal Cancer—Colorectal and Anal. 453Background: More than 70% of hepatocellular carcinoma (HCC) patients are in the intermediate or advanced stages at the time of diagnosis. View Meetings. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone Background: First-line atezolizumab (atezo) + bevacizumab (bev) has been approved in > 80 countries based on significantly longer survival vs sorafenib (sor) in systemic treatment (tx)–naive patients (pts) with unresectable HCC in IMbrave150 (NCT03434379; Finn NEJM 2020). In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. All Rights Reserved Worldwide. 0 ASCO GI data conference call. Methods: We conducted phase II study evaluating the efficacy of neo-adjuvant nivolumab and ipilimumab followed by adjuvant nivolumab in pts with resectable Purpose: To provide an overview of the key findings from studies in upper gastrointestinal, hepatobiliary, pancreas, and colorectal malignancies presented at ASCO GI 2022. KEYNOTE-394 is a randomized, double-blind, phase 3 study conducted in Asia to evaluate the efficacy and safety 2022 ASCO Gastrointestinal Cancers Symposium - Oral Abstract Session . The 2022 ASCO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation by these sponsorship donors. Information & Authors Background: Immune checkpoint inhibitors (ICI) have made significant breakthroughs in late-stage gastric cancer. 2022 ASCO Gastrointestinal Cancers Symposium. January 23 to January 25. 8) Patients that were MRD-negative post surgery received no significant benefit from ACT (Absolute risk reduction of only 1. ASCO GI ASCO Gastrointestinal Cancers Symposium . COSMIC-021 (NCT03170960) is evaluating the combination of cabozantinib with atezolizumab, an anti-PD-L1 inhibitor, in patients with advanced solid tumors. Clinically meaningful long-term survival benefit with NIVO + Background: Addition of an anti-PD-1 antibody to trastuzumab reportedly enhances ADCC activity of trastuzumab, leading to an additive antitumor effect. September 24, 2024. Dr. ASCO GI 2022 activity in untreated pts with advanced G/GEJ adenocarcinoma were presented in ASCO GI 2022 (abstract#308). Sintilimab, a human IgG4 monoclonal antibody that binds to programmed cell death receptor-1(PD-1), has shown Phase 1/2 studies have evaluated the tyrosine kinase inhibitor (TKI) cabozantinib in combination with the ICIs atezolizumab and durvalumab and have demonstrated encouraging clinical activity, with data suggesting greater benefit in RAS wild-type (wt) versus RAS mutant (mut) mCRC (Abrams TA, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. Therefore, durvalumab plus chemotherapy could be a new standard-of-care Background: Our previous analysis of data from the prospective, observational GALAXY study (UMIN000039205) reported post surgical detection of molecular residual disease (MRD) to be prognostic of patient (pt) outcomes and the most significant risk factor for recurrence regardless of BRAF V600E status. HIMALAYA (NCT03298451) evaluated the efficacy ASCO Gastrointestinal Cancers Symposium . 2022 ASCO Gastrointestinal Cancers Symposium - Poster Session . . Session Type MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Duke University Medical Center, Durham, NC, UNC Lineberger American Society of Clinical Oncology. TOPAZ-1, the first global phase 3 study to evaluate use of immunotherapy in the first-line setting in advanced biliary tract cancers (BTCs), demonstrated that adding the PD-L1 inhibitor durvalumab to gemcitabine and cisplatin—the current first-line standard of care—significantly improves overall survival and other efficacy outcomes without exacerbating ASCO Gastrointestinal Cancers Symposium . 6 mo follow-up, Cologuard 2. Uncover how global knowledge-sharing translates to high-quality care The 2022 ASCO Gastrointestinal (GI) Cancers Symposium, to be held from January 20 to 22, 2022, will showcase groundbreaking new therapies across the spectrum of GI malignancies, new technologies advancing the field, The 2022 ASCO Gastrointestinal (GI) Cancers Symposium will take place at Moscone West in San Francisco from January 20-22. These data will be presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium on Friday, Jan. SNO/ASCO CNS Metastases Conference launch. The 2022 ASCO Gastrointestinal (GI) Cancers Symposium, to be held from January 20 to 22, 2022, will showcase groundbreaking new therapies across the spectrum of GI malignancies, new technologies advancing the field, and innovative strategies to expand access to precision medicine. Also, durvalumab monotherapy was non-inferior to sorafenib. Daiichi Sankyo, Inc. Rapid Oral Abstract Session. We investigated the safety and tolerability of nivolumab plus trastuzumab combined 2022 ASCO Gastrointestinal Cancers Symposium - Trials in Progress Poster Session . Information & Authors 241Background: At interim analysis of the phase 3, randomized, double-blind KEYNOTE-590 (NCT03189719) study, 1L pembrolizumab (pembro) + chemotherapy (chemo) vs chemo alone provided superior OS, PFS, and ORR with a ASCO Gastrointestinal Cancers Symposium . This clinically meaningful tx benefit was maintained with an additional 12 months Background: In pts with resectable gastric adenocarcinoma or OGA, radical surgery is the only curative option and perioperative chemotherapy seems worthless for those with MSI/dMMR tumors. COVID-19 testing will be available for registered attendees who experience symptoms on site and for registered 1 - 20 out of 666 Results for "2022 ASCO Gastrointestinal Cancers Symposium" 666 Results Select All . check_circle_outline Network. 2022 ASCO Gastrointestinal Cancers Symposium - Trials in Progress Poster Session . The results were presented at the ASCO Gastrointestinal Cancers Symposium 2022 by Ghassan K. KRAS mutations occur in approximately 90% of pancreatic cancer, and approximately 2% of these are KRAS G12C mutations. Nevertheless, the prognosis of patients with G/GEJ cancer still remain variation after normative therapy. Gastrointestinal Cancers Benefit of First-Line Pembrolizumab Plus Chemotherapy in Esophageal Cancer Bolstered by Longer-Term Efficacy, Safety, and QOL Data From KEYNOTE-590 January 27, 2022 Updates of landmark trials of immune checkpoint inhibitors as first-line therapy for advanced HER2-negative esophagogastric cancers were presented at the 2022 ASCO Get a sneak peek of the cutting-edge research shaping GI cancer care. Oral Abstract Session Fundación Arturo López Pérez, Santiago, Chile, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China, The Cancer Contribute your cutting-edge science for the chance to present at the premier event in global oncology. Bridge-to-transplant stereotactic body radiation therapy in patients with hepatocellular carcinoma and advanced cirrhosis. NCT04006262. Abstract 238. View Now. Information & Authors Purpose To provide an overview of the key findings from studies in upper gastrointestinal, hepatobiliary, pancreas, and colorectal malignancies presented at ASCO GI 2022. We evaluated if This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. ET. 3% with a range of 15. Information & Authors The ASCO Post, in partnership with the American Society of Clinical Oncology, communicates news of the highest quality multidisciplinary cancer care to a broad audience of oncology professionals and members. calendar_today Dates expand_less . He is the Director of 12Background: Encorafenib (E) and cetuximab (C) offers short-lived response and survival benefit for patients (pts) with MSS, BRAFV600E metastatic colorectal cancer (CRC). Abou-Alfa; Liver Unit and HPB Oncology Area, Cl Clin Oncol 2022;40[suppl 4]. 1%). Presented January 21, 2022. BRAF + EGFR inhibition induced a By Caroline Helwick / February 10, 2022 / 2022 ASCO Gastrointestinal Cancers Symposium. Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial. The PD-1/CTLA-4 dual blockade has consistently demonstrated higher Background: Addition of an anti-PD-1 antibody to trastuzumab reportedly enhances ADCC activity of trastuzumab, leading to an additive antitumor effect. Combining TACE with dual ICI therapy has been shown to be safe and feasible. Tumour agnostic treatments in GI cancer Free access to ASCO publications and discounted meeting registration. Fri. ASCO GI 2022:Abs 121; Saeed A, et al. 2025 ASCO Genitourinary Cancers In phase 1/2 trials, ICIs in combination with VEGFR2 multi-kinase inhibitors (MKIs) have demonstrated encouraging clinical activity in mCRC, including atezolizumab and durvalumab (ICIs) in combination with the MKI cabozantinib, with data suggesting a greater benefit in RAS wild-type (wt) vs mutant (mut) disease (Abrams TA, et al. Want to read more? Please login or register first to view this content. 1 Transarterial chemoembolization (TACE) is the preferred treatment for patients with Furthermore, the Japanese Clinical Oncology Group (JCOG) conducted the JCOG1109 NExT study, a three-arm phase III trial to evaluate the superiority of DCF versus chemoradiation plus CF versus CF Free Access Colorectal Cancer Jan 19, 2022 Integrated approach to collecting patient reported toxicities in a colorectal cancer trial. Sponsorship Donors ASCO Gastrointestinal Cancers Symposium . asco. The studies highlighted were selected by the authors based on their significant discoveries and potential impact on Phase 1/2 studies evaluating cabozantinib (an inhibitor of MET, AXL, and VEGFR2) in combination with atezolizumab and durvalumab have demonstrated encouraging clinical activity (Abrams TA, et al. Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians are presenting research studies at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Symposium. “Hepatocellular carcinoma is a leading cause of cancer death across the world, and there are limited treatment options shown to extend survival for patients following treatment with ASCO Gastrointestinal Cancers Symposium - Research Summaries for Patients; The American Society of Clinical Oncology (the Society) is governed by a volunteer Board of Directors (including five Board officers) elected by ASCO’s member oncologists. Full Schedule My Agenda . 19. Presented in part at ASCO GI 2022, San Francisco, CA, January 20-23, 2022; and the 2023 ASCO Plenary Series, virtual, April 10, 2023. Here, we report interim results. Hours of Operation 8:30 AM–5:00 PM (EDT) Closed on weekends and US holidays. Zani has shown preliminary antitumor activity and tolerability in pts with HER2+ gastroesophageal adenocarcinoma as monotherapy/with chemo in Phase 1/2 studies (NCT02892123, NCT03929666). Explore titles of the more than 830 abstracts that will be presented at January's meeting. Recent data has suggested that Day 1-only anti-CTLA4 dosing could potentially lead to a stronger immune response with a tolerable safety profile though this novel schedule The American Society of Clinical Oncology elected Elizabeth A. Login Register. Register Now. 2025 ASCO Gastrointestinal Cancers Symposium . This year’s meeting offers new, innovative findings in GI cancer treatment, research, and care. Information & Authors Although patients with a PD-L1 combined positive score (CPS) ≥ 5 show pronounced OS improvements, those with a PD-L1 CPS < 5 also benefit based on 24-month data presented at the 2022 ASCO Gastrointestinal Cancers Symposium (Abstract 240). Background: Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) has the potential to select patients who may benefit more from standard-of-care (SOC) adjuvant chemotherapy (ACT) by accurately assessing recurrence-risk post-surgery and by evaluating ACT efficacy. 8% between colorectal, pancreatic, and gastroesophageal tumors (Hecht R. 11208 Waples Mill Road, Suite 112 Fairfax, VA 22030 Phone: 888-788-1522 (within the US) 703-449-6418 (outside the US) Fax: 703-563-2715. Eligibility to volunteer, join ASCO committees, and advocate for cancer care. Pages: 242. Information & Authors Information Published In. The slides are high-resolution images suitable for colorectal malignancies presented at ASCO GI 2022. Moscone West, San Francisco, United States of America. Get a sneak peek of the cutting-edge research shaping GI cancer care. TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma. Information & Authors 321Background: The phase III CheckMate 577 study resulted in adjuvant nivolumab becoming a new standard of care for patients with completely resected E/GEJ cancer with residual pathologic disease post neoadjuvant chemoradiotherapy. Below, we review some of the most talked about abstracts that were presented at the meeting. 68% of ACT-treated patients cumulatively cleared their ctDNA by week 24 and had significantly better outcomes compared to patients who remained ctDNA-positive (HR 15. Free access. 1 Patients who tested Background: CheckMate 649 is a randomized, global phase 3 study of 1L programmed death-1 (PD-1) inhibitor–based therapies in advanced non-HER2-positive GC/GEJC/EAC that demonstrated superior overall survival (OS) with NIVO + chemo vs chemo, leading to approvals in the US and other countries. Get ready to learn about the most innovative science in gastrointestinal (GI) cancers at the ASCO GI Cancers Symposium from January 20 to 22, 2022. Information & Authors Background: We have conducted randomized three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel plus CF (DCF) versus radiation with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer, which is on-follow-up for primary analysis planned in 2023 (JCOG 1109). Tremelimumab plus durvalumab improved the overall survival (OS) of patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib. Pages: 378. Multidisciplinary Thoracic Cancers Symposium launch. However, the prognosis still remains poor, novel treatment options are urgently need. Methods We reviewed the abstracts presented at ASCO GI 2022. Multidisciplinary Head & Neck Symposium launch. Background: Neoadjuvant treatment is the standard care for locally advanced esophageal squamous cell cancer (ESCC). Information & Authors ASCO would like to thank its cosponsors for their support and its committees for their volunteer efforts. Exclusive networking opportunities, with access to ASCO Membership Directory and myConnection. Access the presentation videos and slides on your laptop, PC, or view using your mobile device. Share on. 2022. Sub Track. Abs 379). Jacquelyne Janean Gaddy et al. This abstract does not include a full text component. Here, we present an updated analysis and correlation of ctDNA American Society of Clinical Oncology. Information & Authors The positive results of durvalumab, a programmed cell death ligand 1 antibody, plus tremelimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, were also presented at the 2022 American Society Clinical Oncology Gastrointestinal Cancers Symposium as superior to sorafenib in prolonging the overall survival; this combination is GALAXY study in CIRCULATE-Japan. 20 - 22 Jan 2022. ASCO offers premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide. Background: KRAS, the most frequently mutated oncogene in cancer, is a key mediator of the RAS/MAPK signaling cascade that promotes cellular growth and proliferation. Moreover, the addition of durvalumab did not lead to increased toxicity. This is an ASCO Meeting Abstract from the 2022 ASCO Annual In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. Methods: Eligible patients (pts) with ESCC of clinical stage IB, II, III (excluding T4) (UICC 7th) from 44 The ASCO Gastrointestinal Cancers Symposium is a specialized meeting designed to highlight the latest science in GI cancers and other information oncologists of all subspecialties need to know now, in order to provide the highest quality of care to patients. January 19, 2022. in the screening and treatment of gastrointestinal cancers will be featured in the Background: DANTE evaluates atezolizumab in the perioperative treatment of resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with FLOT. The studies highlighted were selected by the authors based on their signicant discoveries and potential impact on clinical practice. Upcoming Meetings . JCOG1109 (UMIN000009482) compared the doublet and triplet of chemotherapy and chemoradiotherapy as neoadjuvant treatment. San Francisco, California, United States. An earlier Phase 2b study in patients with advanced pancreatic cancer showed an improvement in Background: Zani, also known as ZW25, is a novel HER2-targeted bispecific antibody that targets two distinct extracellular domains of HER2. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Therapeutics. Durvalumab plus chemotherapy was superior to chemotherapy alone as a frontline therapy for patients with advanced biliary tract cancer in the phase 3 TOPAZ-1 trial. 40. Furthermore, during ASCO-GI 2021, results from early phase trials have This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. The Symposium, a hybrid event, will be held at Moscone West in Cadonilimab, a tetrameric bispecific antibody targeting PD-1 and CTLA-4, combined with chemotherapy showed promising activity in untreated pts with advanced G/GEJ adenocarcinoma were presented in ASCO GI 2022 (abstract#308). Adjuvant Therapy for Stage II Colon This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. With these additional 12 months of data, the study's findings continue to show both OS and PFS benefits in all key prespecified subgroups of interest based on disease histology and PD 8Background: Standard 1L therapies for mCRC include a fluoropyrimidine with oxaliplatin and/or irinotecan, and a biologic agent. The 2022 ASCO Gastrointestinal (GI) Cancers Symposium will take place at Moscone West in San Francisco from January 20-22. Efficacy of immune checkpoint inhibitors for gastrointestinal cancers with SWI/SNF complex genetic alterations. DOI. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center in New York, New York. In the KEYNOTE-811 study, pembrolizumab in combination with trastuzumab plus chemotherapy resulted in a durable response. Finn RS, Qin S, Ikeda M, et al: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. 17. Support. Sintilimab plus lenvatinib as conversion therapy in patients with unresectable locally intermediate to advanced hepatocellular carcinoma: A single-arm, single-center, open-label, phase 2 study. ASCO Gastrointestinal Cancers Symposium - Research Summaries for Patients; October 17, 2022. Information & Authors ASCO’s meeting slides and videos program enables professionals who are unable to attend a meeting to access the delivery of that practice-changing science through the purchase of those assets after the conclusion of the meetings. Attendees can expect highly interactive sessions with multidisciplinary perspectives based on the latest international research advances, presentation of the newest innovations and implications for optimal patient care, enhanced Phase 1/2 studies have evaluated the tyrosine kinase inhibitor (TKI) cabozantinib in combination with the ICIs atezolizumab and durvalumab and have demonstrated encouraging clinical activity, with data suggesting greater benefit in RAS wild-type (wt) versus RAS mutant (mut) mCRC (Abrams TA, et al. February 17, 2022. Abstract #190). 4_suppl. Meeting Abstract: 2022 ASCO Gastrointestinal Cancers Symposium. At the time of the protocol This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. Authors. Hepatobiliary Cancer. Abstracts & Presentations. ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. Information & Authors The frequency of HLA LOH among advanced GI solid tumor cancers in the Tempus real-world dataset is 16. TACE, TKI and PD-1 antibody are all recommended for patients with unresectable HCC (uHCC) according to Chinese HCC 2022 ASCO Gastrointestinal Cancers Symposium. 3 months) exceeds historical results of 3 months across 19 trials (Manax ASCO GI 2019) and compares favorably with the 6. Esophageal and Gastric Cancer,Other GI Cancer. 1,2,3 Hepatocellular carcinoma (HCC) accounts for 75%–85% of liver cancers. Information & Authors 2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 © American Society of Clinical Oncology (ASCO). Rapid Abstract Session A: Cancers of the Esophagus and Stomach. Abstract 379. The Symposium fosters dialogue among oncologists and other members of the cancer care ASCO GI 2022. Methods: A systematic review was performed using combined terms related to “stomach cancer”, “gastric cancer”, “gastroesophageal cancer”, “immune checkpoint ASCO Gastrointestinal Cancers Symposium . Sat. Medical writing support under the direction of the authors was provided Background: Eryaspase, asparaginase encapsulated in red blood cells is an investigational product under development. 2. ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial aiming to describe the performance of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer with a potentially actionable genomic variant. Bristol Myers Squibb Daiichi Sankyo, Inc. 1 - 20 out of 5198 Results for "2022 ASCO Annual Meeting" 5198 Results Select All . Supported by Mirati Therapeutics, Inc and also supported by the Cancer Center Core Grant P30 CA 008748 to Memorial Sloan Kettering. Here we present an analysis from GALAXY study, an observational Free Access Colorectal Cancer Jan 19, 2022 Integrated approach to collecting patient reported toxicities in a colorectal cancer trial. Abstract # 238. The 2022 Gastrointestinal Cancers Symposium encompassed more than 650 abstracts across solid tumors. We investigated the safety and tolerability of nivolumab plus trastuzumab combined This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. Session Title. Webcast (opens in new window) Presentation (opens in new window) Quick Links. The positive results of durvalumab, a programmed cell death ligand 1 antibody, plus tremelimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, were also presented at the 2022 American Society Clinical Oncology Gastrointestinal Cancers Symposium as superior to sorafenib in prolonging the overall survival; this combination is ASCO GI 2022 Trial Phase 3, HIMALAYA. At a median of 8. ATTRIBUTION TO THE 2022 ASCO Background: A single priming dose of T (anti-CTLA-4) added to D (anti-PD-L1) in the STRIDE (Single T Regular Interval D) regimen, formerly T300+D, showed encouraging clinical activity and limited toxicity in a phase 2 uHCC study (Study 22, NCT02519348), suggesting single exposure to T is sufficient to improve upon D activity. org for the latest in-person attendee requirements and protocols. The encapsulated asparaginase induces the degradation of asparagine and glutamine, crucial for cancer cell growth and survival. Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142. Information & Authors Patel, Alejandra Negro, Ghassan K. Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress. AK117 is a novel humanized IgG4 anti-CD47 antibody without hemagglutination effect. January 23-25, the ASCO Foundation, by these generous donors. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2025 American Society of Clinical Oncology ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. Track. Poster Discussion Session. The studies highlighted were selected by the authors based on their significant discoveries and potential impact on This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. 8 months (Abstract 241). A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. Background: The anti–PD-1 antibody pembro showed efficacy and manageable safety in the global phase 2 KEYNOTE-224 and phase 3 KEYNOTE-240 studies of patients (pts) with previously treated advanced HCC, a population of high unmet need. The primary analysis of DESTINY-CRC01 (DS8201-A-J203; NCT03384940), a phase 2, open-label, multicenter study of T-DXd in pts with HER2-expressing mCRC showed promising antitumor activity and a 2022 ASCO Gastrointestinal Cancers Symposium. Thu. 1 months in 2 nd line patients in NAPOLI-1. It uncovers the significant treatment prospects of immune checkpoint inhibitors combination therapies. ASCO Gastrointestinal Cancers Symposium . N Engl J Med 382:1894-1905, 2020. For the first time, a phase III study has shown an overall survival benefit for upfront treatment using immunotherapy plus chemotherapy in advanced ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer October 23, 2006 Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline May 16, 2022. 1 D + GC significantly improved overall survival (OS) versus placebo (PBO) + This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. Methods: We reviewed the abstracts presented at ASCO GI 2022. 10. Pages: 379. The 2022 ASCO Gastrointestinal (GI) Cancers Symposium offers new, innovative findings in GI cancer treatment, research, and care. check_circle_outline Volunteer. Uncover how global knowledge-sharing translates to high-quality care for all people affected by cancer worldwide. The ASCO Post, in partnership with the American Society of Clinical Oncology, communicates news of the highest quality multidisciplinary cancer care to a broad audience of oncology professionals and members. Liver cancer is the third most common cause of This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. 21 at 10:15 a. June 02, 2022. 18. ASCO GI In phase 1/2 trials, ICIs in combination with VEGFR2 multi-kinase inhibitors (MKIs) have demonstrated encouraging clinical activity in mCRC, including atezolizumab and durvalumab (ICIs) in combination with the MKI cabozantinib, with data suggesting a greater benefit in RAS wild-type (wt) vs mutant (mut) disease (Abrams TA, et al. Mittendorf, MD, PhD, MHCM, FASCO, to lead as its President beginning in June 2026. January 19, 2022 11:00 AM EST. type (wt) versus RAS mutant (mut) mCRC (Abrams TA, et al. This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. Methods: A pre-planned secondary objective of HIMALAYA GASTROINTESTINAL CANCER—GASTROESOPHAGEAL, PANCREATIC, AND HEPATOBILIARY Background: The NIVOLVE trial was designed to assess the efficacy and safety of nivolumab as an adjuvant therapy for HCC, and to identify biomarkers predictive of recurrence in patients after SR or RFA (Registration # UMIN 000026648). With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone Background: Atezo + bev has been approved globally for pts with unresectable HCC who have not received prior systemic therapy, based on results from IMbrave150 (NCT03434379). As such, HLA LOH offers a definitive tumor versus normal discriminator target for CAR T-cell therapy. et al. 2025 ASCO Gastrointestinal Cancers Symposium. ASCO GI 2022. Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China, Peking University Cancer Hospital & Institute, Beijing, China, Department of OS in 3 rd line (6. Journal of Clinical Oncology. Information & Authors This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. 6%-20. Clinical trial information: NCT04390399. Background: Cabozantinib, a multiple receptor tyrosine kinase inhibitor, promotes an immune-permissive environment which may enhance the activity of immune checkpoint inhibitors. #ASCO25. Contact the ASCO Gastrointestinal Cancers Symposium Customer Service Center. This study aimed to evaluate the influence of preoperative 2022 ASCO Annual Meeting. Sponsorship Donors (Gold) Sponsorship Donors (Silver) Body. News. Clinical Trial Registration Number. ASCO Genitourinary Cancers Symposium . The ASCO Annual Meeting is The Place to Be Heard! Submit Today. Ken Kato . July 31, 2024. Volume 40 • Number 4_suppl • February 2022. GlaxoSmithKline Oncology. NIVO may enhance antitumor activity in combination with 1L standard therapies within a subset of patients (pts) with mCRC. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone Background: TOPAZ-1 (NCT03875235) is a randomized, double-blind, global, Phase 3 study evaluating the efficacy and safety of durvalumab (D) in combination with (+) gemcitabine and cisplatin (GC) as first-line treatment for patients (pts) with advanced biliary tract cancer (BTC). Blockade of CD47-SIRPa pathway by AK117 leads to a promising therapeutic strategy for cancer treatment with favorable safety features. January 23-25, 2025. TOPAZ-1: Overall Survival Prolonged With First-Line Immunotherapy Plus Chemotherapy in Biliary Tract Cancer. Sponsorship Donors (Gold) Sponsorship Donors (Silver) The use of circulating tumor DNA (ctDNA) assays in early-stage colorectal cancer is highly prognostic for recurrence and may help identify patients who could benefit from adjuvant chemotherapy, according to findings from the GALAXY trial, presented at the 2022 ASCO Gastrointestinal Cancers Symposium by investigators from Japan. The study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 20-22, 2022, in San Francisco, California. ASCO GI 2022 This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. Further, neoadjuvant therapy showed highlighted application value and Immuno-oncology therapy is newly 2022 ASCO Gastrointestinal Cancers Symposium - Trials in Progress Poster Session . The American Society of Clinical Oncology seeks to provide the highest-quality resources in education, policy, the pioneering of clinical research, Abstract submissions for the 2022 ASCO Gastrointestinal Cancers Symposium are now being accepted! Submit your research to the leading, multidisciplinary event for new, innovative research in GI 2022 ASCO Gastrointestinal Cancers Symposium - Oral Abstract Session . Cadonilimab, a tetrameric bispecific antibody targeting PD-1 and CTLA-4, combined with chemotherapy showed promising activity in untreated pts with advanced G/GEJ adenocarcinoma were presented in ASCO GI 2022 (abstract#308). 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2025 American Society of Clinical Oncology The 2023 ASCO Gastrointestinal Cancers Symposium is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors. Session Type. ASCO-GI 2022. Background: D2 radical surgery and adjuvant chemotherapy is mainly treatment scheme of Gastric/gastroesophageal junction (G/GEJ) cancer. AACR/ASCO Methods in Clinical Cancer Research Workshop launch. Manisha Palta. 2022 ASCO Annual Meeting - Plenary Session . Visit the Health and Safety page at gi. Information & Authors Background: T-DXd is an antibody-drug conjugate of a humanized anti-HER2 antibody bound to a topoisomerase I inhibitor by a cleavable linker. January 23-25, 2025 • Moscone West • San Francisco, CA & Online the ASCO Foundation, by these generous donors. m. May 30 - June 3, 2025 • McCormick Place • Chicago, IL & Online. emj qak ldresb zqmlw iyi ripbt hedrcvh tpfara fho gltm